Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Novel Fabrication of MicroRNA Nanoparticle-Coated Coronary Stent for Prevention of Post-Angioplasty Restenosis

  • Che, Hui-Lian (Department of Biomedical Sciences and BK21 PLUS Center for Creative Biomedical Scientists) ;
  • Bae, In-Ho (Heart Research Center, Chonnam National University Hospital) ;
  • Lim, Kyung Seob (Heart Research Center, Chonnam National University Hospital) ;
  • Uthaman, Saji (Department of Biomedical Sciences and BK21 PLUS Center for Creative Biomedical Scientists) ;
  • Song, In Taek (The Graduate School of Nanoscience and Technology and Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST)) ;
  • Lee, Haeshin (The Graduate School of Nanoscience and Technology and Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST)) ;
  • Lee, Duhwan (Center for Self-assembly and Complexicity, Department of Chemistry, Pohang University of Science and Technology) ;
  • Kim, Won Jong (Center for Self-assembly and Complexicity, Department of Chemistry, Pohang University of Science and Technology) ;
  • Ahn, Youngkeun (Heart Research Center, Chonnam National University Hospital) ;
  • Park, In-Kyu (Department of Biomedical Sciences and BK21 PLUS Center for Creative Biomedical Scientists) ;
  • Jeong, Myung-Ho (Heart Research Center, Chonnam National University Hospital)
  • Received : 2015.01.12
  • Accepted : 2015.07.16
  • Published : 2016.01.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: MicroRNA 145 is known to be responsible for cellular proliferation, and its enhanced expression reportedly inhibits the retardation of vascular smooth muscle cell growth specifically. In this study, we developed a microRNA 145 nanoparticle immobilized, hyaluronic acid (HA)-coated stent. Materials and Methods: For the gene therapy, we used disulfide cross-linked low molecular polyethylenimine as the carrier. The microRNA 145 was labeled with YOYO-1 and the fluorescent microscopy images were obtained. The release of microRNA 145 from the stent was measured with an ultra violet spectrophotometer. The downstream targeting of the c-Myc protein and green fluorescent protein was determined by Western blotting. Finally, we deployed microRNA 145/ssPEI nanoparticles immobilized on HA-coated stents in the balloon-injured external iliac artery in a rabbit restenosis model. Results: Cellular viability of the nanoparticle-immobilized surface tested using A10 vascular smooth muscle cells showed that MSN exhibited negligible cytotoxicity. In addition, microRNA 145 and downstream signaling proteins were identified by western blots with smooth muscle cell (SMC) lysates from the transfected A10 cell, as the molecular mechanism for decreased SMC proliferation that results in the inhibition of in-stent restenosis. MicroRNA 145 released from the stent suppressed the growth of the smooth muscle at the peri-stent implantation area, resulting in the prevention of restenosis at the post-implantation. We investigated the qualitative analyses of in-stent restenosis in the rabbit model using micro-computed tomography imaging and histological staining. Conclusion: MicroRNA 145-eluting stent mitigated in-stent restenosis efficiently with no side effects and can be considered a successful substitute to the current drug-eluting stent.

Keywords

Acknowledgement

Supported by : Korean Society of Cardiology, National Research Foundation of Korea (NRF)

References

  1. Thomas MK, Gupta YK. Drug-eluting stents: a pharmacoclinical perspective. Natl Med J India 2006;19:195-9.
  2. Zhu D, Jin X, Leng X, et al. Local gene delivery via endovascular stents coated with dodecylated chitosan-plasmid DNA nanoparticles. Int J Nanomedicine 2010;5:1095-102.
  3. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of instent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8. https://doi.org/10.1161/01.CIR.100.18.1872
  4. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501. https://doi.org/10.1056/NEJM199408253310802
  5. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation 2002;106:2734-40. https://doi.org/10.1161/01.CIR.0000038982.49640.70
  6. Nikol S. Possible uses of gene therapy in reducing coronary restenosis. Heart 1997;78:426-8. https://doi.org/10.1136/hrt.78.5.426
  7. Gershlick AH. Drug eluting stents in 2005. Heart 2005;91 Suppl 3:iii24-31. https://doi.org/10.1136/hrt.2004.047183
  8. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80. https://doi.org/10.1056/NEJMoa012843
  9. Lompre AM, Hadri L, Merlet E, et al. Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: A new perspective for in-stent restenosis gene therapy. Gene Ther 2013;20:901-12. https://doi.org/10.1038/gt.2013.13
  10. Forbes SP, Alferiev IS, Chorny M, Adamo RF, Levy RJ, Fishbein I. Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: Implications for gene therapy of restenosis. Atherosclerosis 2013;230:23-32. https://doi.org/10.1016/j.atherosclerosis.2013.06.002
  11. Fishbein I, Chorny M, Adamo RF, et al. Endovascular gene delivery from a stent platform: gene-eluting stents. Angiol Open Access 2013;1. pii:109.
  12. Brito LA, Chandrasekhar S, Little SR, Amiji MM. Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis. Biomed Eng Online 2010;9:56. https://doi.org/10.1186/1475-925X-9-56
  13. Li JM, Newburger PE, Gounis MJ, Dargon P, Zhang X, Messina LM. Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model. Gene Ther 2010;17:1279-87. https://doi.org/10.1038/gt.2010.69
  14. Che HL, Bae IH, Lim KS, et al. Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model. Biomaterials 2012;33:8548-56. https://doi.org/10.1016/j.biomaterials.2012.07.045
  15. Hwang do W, Son S, Jang J, et al. A brain-targeted rabies virus glycoproteindisulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011;32:4968-75. https://doi.org/10.1016/j.biomaterials.2011.03.047
  16. Goueffic Y, Guilluy C, Guerin P, Patra P, Pacaud P, Loirand G. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res 2006;72:339-48. https://doi.org/10.1016/j.cardiores.2006.07.017
  17. Muthiah M, Islam MA, Cho CS, Hwang JE, Chung IJ, Park IK. Substratemediated delivery of microRNA-145 through a polysorbitol-based osmotically active transporter suppresses smooth muscle cell proliferation: implications for restenosis treatment. J Biomed Nanotechnol 2014;10:571-9. https://doi.org/10.1166/jbn.2014.1737
  18. Ye YC, Xie H, Zeng Y, Zhao X, Tian Z, Zhang S. Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. PLos One 2013;8:e78667. https://doi.org/10.1371/journal.pone.0078667
  19. Al Ali J, Franck C, Filion KB, Eisenberg MJ. Efficacy and safety of drug eluting stents versus coronary artery bypass grafting: a metaanalysis of randomized controlled trials. Can J Cardiol 2013;29:S284.
  20. Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics 2014;4:175-200. https://doi.org/10.7150/thno.7210
  21. Hong YJ, Jeong MH, Ahn Y, Kang JC. The efficacy and safety of drugeluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction (KAMIR). Int J Cardiol 2013;163:1-4. https://doi.org/10.1016/j.ijcard.2012.02.003
  22. Paul A, Shao W, Shum-Tim D, Prakash S. The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNA$_{Ang1+VEGF}$ nanoparticles. Biomaterials 2012;33: 7655-64. https://doi.org/10.1016/j.biomaterials.2012.06.096
  23. Lemkine GF, Demeneix BA. Polyethylenimines for in vivo gene delivery. Curr Opin Mol Ther 2001;3:178-82.
  24. Li D, Tang X, Pulli B, et al. Theranostic nanoparticles based on bioreducible polyethylenimine-coated iron oxide for reduction-responsive gene delivery and magnetic resonance imaging. Int J Nanomedicine 2014;9:3347-61.
  25. Park S, Bhang SH, La WG, Seo J, Kim BS, Char K. Dual roles of hyaluronic acids in multilayer films capturing nanocarriers for drug-eluting coatings. Biomaterials 2012;33:5468-77. https://doi.org/10.1016/j.biomaterials.2012.04.005
  26. Travis JA, Hughes MG, Wong JM, Wagner WD, Geary RL. Hyaluronan enhances contraction of collagen by smooth muscle cells and adventitial fibroblasts: role of CD44 and implications for constrictive remodeling. Circ Res 2001;88:77-83. https://doi.org/10.1161/01.RES.88.1.77

Cited by

  1. Long-term preclinical evaluation of bioabsorbable polymer-coated drug-eluting stent in a porcine model vol.25, pp.7, 2016, https://doi.org/10.1007/s13233-017-5067-z
  2. Stimuli-Regulated Smart Polymeric Systems for Gene Therapy vol.9, pp.4, 2016, https://doi.org/10.3390/polym9040152
  3. microRNAs in cardiovascular disease – clinical application vol.55, pp.5, 2016, https://doi.org/10.1515/cclm-2016-0576
  4. microRNAs in cardiovascular disease – clinical application vol.55, pp.5, 2016, https://doi.org/10.1515/cclm-2016-0576